Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations.
Adult asthma
Asthma severity
Cost analysis
Cost burden
Direct costs
GINA updates
SABA overuse
Türkiye
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
07
12
2023
accepted:
04
10
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
This cost of illness study aimed to determine economic burden of short-acting β2-agonist (SABA) overuse in Türkiye from payer perspective with respect to the updated GINA 2022 treatment recommendations. A total of 3,034,879 asthma patients comprised the study population, via estimations extrapolated from the Türkiye arm of the global SABINA III study. The economic burden (costs related to the drug use and severe exacerbations) was compared in subgroups of overall (≥ 0 canisters/year) vs. GINA-recommended (0-2 canisters/year, hypothetical population) SABA use and in subgroups of appropriate use (0-2 canisters/year, real population) vs. overuse (≥ 3 canisters/year) of SABA with extrapolation of SABINA Türkiye data to the Türkiye asthma population. Recommended SABA use was predicted to prevent 127,505 of 157,512 severe exacerbations per year in mild asthma patients and 2,668,916 of 3,262,800 severe exacerbations per year in moderate-severe asthma patients. Annual cost burden of not applying recommended SABA use (overall [≥ 0 canisters/year] vs. GINA-recommended [0-2 canisters/year] SABA use) in mild asthma and moderate-severe asthma patients was calculated to be €20.43 million and €427.65 million in terms of severe exacerbations, and to be €829,352 and €7.20 million in terms of drug costs, respectively. The total annual economic burden arising from not applying recommended SABA use was estimated to be €456.11 million. Appropriate use (0-2 canisters/year) vs. overuse (≥ 3 canisters/year) of SABA was associated with decreased frequency of severe exacerbations per year in mild asthma (from 129,878 to 27,634) and moderate-severe asthma (from 2,834,611 to 428,189) patients. SABA overuse in mild and moderate-severe asthma patients was estimated to yield an additional annual cost of €16.38 million and €385.59 million, respectively in terms of severe exacerbations, and a total €11.30 million additional drug cost. The overall annual economic burden arising from SABA overuse was estimated to be €413.27 million. The estimated annual total economic burden arising from not applying recommended SABA use (€456.11 million) and SABA overuse (€413.27 million) with respect to the updated GINA 2022 treatment recommendations indicates the substantial cost burden of SABA overuse to the Turkish National Health System, corresponding up to 26% of the total direct cost of asthma reported in our country.
Sections du résumé
BACKGROUND
BACKGROUND
This cost of illness study aimed to determine economic burden of short-acting β2-agonist (SABA) overuse in Türkiye from payer perspective with respect to the updated GINA 2022 treatment recommendations.
METHODS
METHODS
A total of 3,034,879 asthma patients comprised the study population, via estimations extrapolated from the Türkiye arm of the global SABINA III study. The economic burden (costs related to the drug use and severe exacerbations) was compared in subgroups of overall (≥ 0 canisters/year) vs. GINA-recommended (0-2 canisters/year, hypothetical population) SABA use and in subgroups of appropriate use (0-2 canisters/year, real population) vs. overuse (≥ 3 canisters/year) of SABA with extrapolation of SABINA Türkiye data to the Türkiye asthma population.
RESULTS
RESULTS
Recommended SABA use was predicted to prevent 127,505 of 157,512 severe exacerbations per year in mild asthma patients and 2,668,916 of 3,262,800 severe exacerbations per year in moderate-severe asthma patients. Annual cost burden of not applying recommended SABA use (overall [≥ 0 canisters/year] vs. GINA-recommended [0-2 canisters/year] SABA use) in mild asthma and moderate-severe asthma patients was calculated to be €20.43 million and €427.65 million in terms of severe exacerbations, and to be €829,352 and €7.20 million in terms of drug costs, respectively. The total annual economic burden arising from not applying recommended SABA use was estimated to be €456.11 million. Appropriate use (0-2 canisters/year) vs. overuse (≥ 3 canisters/year) of SABA was associated with decreased frequency of severe exacerbations per year in mild asthma (from 129,878 to 27,634) and moderate-severe asthma (from 2,834,611 to 428,189) patients. SABA overuse in mild and moderate-severe asthma patients was estimated to yield an additional annual cost of €16.38 million and €385.59 million, respectively in terms of severe exacerbations, and a total €11.30 million additional drug cost. The overall annual economic burden arising from SABA overuse was estimated to be €413.27 million.
CONCLUSIONS
CONCLUSIONS
The estimated annual total economic burden arising from not applying recommended SABA use (€456.11 million) and SABA overuse (€413.27 million) with respect to the updated GINA 2022 treatment recommendations indicates the substantial cost burden of SABA overuse to the Turkish National Health System, corresponding up to 26% of the total direct cost of asthma reported in our country.
Identifiants
pubmed: 39434065
doi: 10.1186/s12890-024-03327-9
pii: 10.1186/s12890-024-03327-9
doi:
Substances chimiques
Adrenergic beta-2 Receptor Agonists
0
Anti-Asthmatic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
524Investigateurs
Deniz Kızılırmak
(D)
Nejat Altıntaş
(N)
İsmet Bulut
(İ)
Tülin Çağatay
(T)
Bilun Gemicioğlu
(B)
Özgür İnce
(Ö)
Kıvılcım Oğuzülgen
(K)
Dilşad Mungan
(D)
Füsun Kalpaklıoğlu
(F)
Ayşe Baççıoğlu
(A)
Funda Aksu
(F)
Murat Altuntaş
(M)
Ferda Öner Erkekol
(FÖ)
Gül Karakaya
(G)
Ali Fuat Kalyoncu
(AF)
Ebru Damadoğlu
(E)
İsmail Hanta
(İ)
Ersoy Altunok
(E)
Adviye Özer
(A)
Sibel Atış Naycı
(SA)
Demet Polat Yuluğ
(DP)
Gazi Gülbaş
(G)
Mecit Süerdem
(M)
Burcu Yormaz
(B)
Emel Ceylan
(E)
Duygu Erge
(D)
Aykut Çilli
(A)
Berat Celil Doğan
(BC)
Fuat Erel
(F)
Can Sevinç
(C)
Ceyda Anar
(C)
Dane Ediger
(D)
Gülseren Pekbak
(G)
Müge Erbay
(M)
Informations de copyright
© 2024. The Author(s).
Références
Ishmael FT. The inflammatory response in the pathogenesis of asthma. J Am Osteopath Assoc. 2011;111(11 Suppl 7):S11–7.
pubmed: 22162373
Mulgirigama A, Barnes N, Fletcher M, Pedersen S, Pizzichini E, Tsiligianni I. A review of the burden and management of mild asthma in adults - Implications for clinical practice. Respir Med. 2019;152:97–104.
pubmed: 31128617
doi: 10.1016/j.rmed.2019.04.024
Global Asthma Network (GAN): The Global Asthma Report. http://globalasthmareport.org/ (2022). Accessed 11 May 2023.
To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.
pubmed: 22429515
pmcid: 3353191
doi: 10.1186/1471-2458-12-204
Tarraf H, Aydin O, Mungan D, Albader M, Mahboub B, Doble A, et al. Prevalence of asthma among the adult general population of five Middle Eastern countries: results of the SNAPSHOT program. BMC Pulm Med. 2018;18(1):68.
pubmed: 29751756
pmcid: 5948696
doi: 10.1186/s12890-018-0621-9
Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med. 2022;205(1):17–35.
pubmed: 34658302
doi: 10.1164/rccm.202109-2205PP
Levy ML, Bacharier LB, Bateman E, Boulet LP, Brightling C, Buhl R, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med. 2023;33(1):7.
pubmed: 36754956
pmcid: 9907191
doi: 10.1038/s41533-023-00330-1
Laforest L, Licaj I, Devouassoux G, Chatte G, Martin J, Van Ganse E. Asthma drug ratios and exacerbations: claims data from universal health coverage systems. Eur Respir J. 2014;43(5):1378–86.
pubmed: 24789951
doi: 10.1183/09031936.00100113
Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326(8):501–6.
pubmed: 1346340
doi: 10.1056/NEJM199202203260801
O’Byrne PM, Reddel HK, Beasley R. The management of mild asthma. Eur Respir J. 2021;57(4):2003051.
pubmed: 33093120
doi: 10.1183/13993003.03051-2020
Ozseker ZF, Aksu K, Mutlu LC, Mutlu P, Ozturk C. Turkish Respiratory Society, Asthma, Allergic Respiratory Disease Scientific Committee. Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction-Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA. Curr Allergy Asthma Rep. 2022;22(10):123–34.
pubmed: 35689764
doi: 10.1007/s11882-022-01038-x
Azzi EA, Kritikos V, Peters MJ, Price DB, Srour P, Cvetkovski B, et al. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey. BMJ Open. 2019;9(8): e028995.
pubmed: 31412998
pmcid: 6701672
doi: 10.1136/bmjopen-2019-028995
FitzGerald JM, Tavakoli H, Lynd LD, Al Efraij K, Sadatsafavi M. The impact of inappropriate use of short acting beta agonists in asthma. Respir Med. 2017;131:135–40.
pubmed: 28947020
doi: 10.1016/j.rmed.2017.08.014
Sadatsafavi M, Tavakoli H, Lynd L, FitzGerald JM. Has asthma medication use caught up with the evidence? A 12-year population-based study of trends. Chest. 2017;151(3):612–8.
pubmed: 27815152
doi: 10.1016/j.chest.2016.10.028
Janson C, Menzies-Gow A, Nan C, Nuevo J, Papi A, Quint JK, et al. SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries. Adv Ther. 2020;37(3):1124–35.
pubmed: 31981105
pmcid: 7089727
doi: 10.1007/s12325-020-01233-0
Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe. 2015;11(1):14–24.
pubmed: 26306100
pmcid: 4487386
doi: 10.1183/20734735.008914
Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872.
pubmed: 31949111
pmcid: 7160635
doi: 10.1183/13993003.01872-2019
Al Zaabi A, Busaidi N, Al Mutairy S, Yorgancıoğlu A, Aksu K, Al-Jahdali H, et al. Overprescription of short-acting β2-agonists is associated with poor asthma symptom control: results from five Middle Eastern countries included in the SABINA International (III) study. Expert Rev Respir Med. 2022;16(7):833–47.
pubmed: 35848074
doi: 10.1080/17476348.2022.2099841
Kaplan A, Mitchell PD, Cave AJ, Gagnon R, Foran V, Ellis AK. Effective asthma management: is it time to let the air out of SABA? J Clin Med. 2020;9(4):921.
pubmed: 32230875
pmcid: 7230470
doi: 10.3390/jcm9040921
Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046.
pubmed: 31249014
doi: 10.1183/13993003.01046-2019
Cabrera CS, Nan C, Lindarck N, Beekman MJHI, Arnetorp S, van der Valk RJP. SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma. Eur Respir J. 2020;55(2):1901858.
pubmed: 31806716
doi: 10.1183/13993003.01858-2019
Bloom CI, Cabrera C, Arnetorp S, Coulton K, Nan C, van der Valk RJP, et al. Asthma-Related Health Outcomes Associated with Short-Acting β
pubmed: 32720299
doi: 10.1007/s12325-020-01444-5
Bateman ED, Price DB, Wang HC, Khattab A, Schonffeldt P, Catanzariti A, et al. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2022;59(5):2101402.
pubmed: 34561293
pmcid: 9068976
doi: 10.1183/13993003.01402-2021
Yorgancıoğlu A, Aksu K, Naycı SA, Ediger D, Mungan D, Gül U, et al. Short-acting β2-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III. BMC Pulm Med. 2022;22(1):216.
pubmed: 35655251
pmcid: 9161536
doi: 10.1186/s12890-022-02008-9
Turktas H, Bavbek S, Sekerel B, Oksuz E, Malhan S. Economic Burden of Adult Asthma in Turkey: A Cost of Illness Study from Payer Perspective. J Respir Med. 2018;2(1):111.
Sullivan PW, Ghushchyan VH, Slejko JF, Belozeroff V, Globe DR, Lin SL. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey. J Allergy Clin Immunol. 2011;127(2):3639-9.e1-3.
doi: 10.1016/j.jaci.2010.10.042
Bavbek S, Malhan S, Mungan D, Misirligil Z, Erdinc M, Gemicioglu B, et al. Economic burden of severe asthma in Turkey: a cost of illness study from payer perspective. Eur Ann Allergy Clin Immunol. 2021;53(3):128–37.
pubmed: 32372589
doi: 10.23822/EurAnnACI.1764-1489.149
Bavbek S, Mungan D, Türktaş H, Mısırlıgil Z, Gemicioğlu B. ADVISE Study Group A. cost-of-illness study estimating the direct cost per asthma exacerbation in Turkey. Respir Med. 2011;105(4):541–8.
pubmed: 21035319
doi: 10.1016/j.rmed.2010.10.011
Valero A, Molina J, Nuevo J, Simon S, Capel M, Sicras-Mainar A, et al. Economic Consequences of the Overuse of Short-Acting ß-Adrenergic Agonists in the Treatment of Asthma in Spain. J Investig Allergol Clin Immunol. 2023;33(2):109–18.
pubmed: 34825651
doi: 10.18176/jiaci.0767
Attar-Zadeh D, Capstick T, Leese D, Arnetorp S, Rapsomaniki E, Da Costa KP, et al. Healthcare costs associated with short-acting β2-agonists in asthma: observational UK SABINA study. BJGP Open. 2023;7(3):BJGPO.2030.015.
doi: 10.3399/BJGPO.2023.0015
Republic of Turkey Social Security Institution: The Medical Enforcement Declaration. https://www.resmigazete.gov.tr/fihrist?tarih=2022-08-25&mukerrer=1 (2022). Accessed 13 May 2023.
Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol. 2013;160(1):93–101.
pubmed: 22948386
doi: 10.1159/000338998
Global Asthma Network (GAN): The Global Asthma Report. http:// www. globa lasth marep ort. org/ (2018). Accessed 15 Apr 2021.
Nordon C, Aubier M, Thabut G, Grimaldi-Bensouda L, Amzal B, Pribil C, et al. The Burden of Severe Asthma in France. Value Health. 2016;19:A560–1.
doi: 10.1016/j.jval.2016.09.1238
Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.
pubmed: 19454036
pmcid: 2698859
doi: 10.1186/1471-2466-9-24
Haahtela T, Herse F, Karjalainen J, Klaukka T, Linna M, Leskelä RL, et al. The Finnish experience to save asthma costs by improving care in 1987–2013. J Allergy Clin Immunol. 2017;139(2):408-14.e2.
pubmed: 27979429
doi: 10.1016/j.jaci.2016.12.001
Turktas H, Bavbek S, Malhan S. The Direct Cost of Asthma in Turkey. Value Health. 2014;17(7):A593.
pubmed: 27202030
doi: 10.1016/j.jval.2014.08.2040
Avdeev S, Voznesenskiy N, Boldina M, Ignatova G, Kostina N, Kulbaisov A, et al. SABA Overuse in Russia - Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study. J Asthma Allergy. 2022;15:371–9.
pubmed: 35368426
pmcid: 8965337
doi: 10.2147/JAA.S350393
Wang C-Y, Lai C-C, Wang Y-H, Wang H-C. The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan. NPJ Prim Care Respir Med. 2021;31(1):19.
pubmed: 33879785
pmcid: 8058069
doi: 10.1038/s41533-021-00231-1
Alzaabi A, Al Busaidi N, Pradhan R, Shandy F, Ibrahim N, Ashtar M, et al. Over-prescription of short-acting β2-agonists and asthma management in the Gulf region: a multicountry observational study. Asthma Res Pract. 2022;8(1):3.
pubmed: 35799290
pmcid: 9260980
doi: 10.1186/s40733-022-00085-5
Loh ZC, Hussain R, Balan S, Saini B, Muneswarao J, Ong SC, et al. Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β2-agonists: A systematic review. PLoS ONE. 2023;18(4): e0283876.
pubmed: 37079594
pmcid: 10118161
doi: 10.1371/journal.pone.0283876
Douglass JA, Goeman DP, McCarthy EA, Sawyer SM, Aroni RA, Stewart K, et al. Over-the-counter β2-agonist purchase versus script: a cross-sectional study. Respir Med. 2012;106(2):223–9.
pubmed: 22040532
doi: 10.1016/j.rmed.2011.09.012
Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017;7(9): e016688.
pubmed: 28947448
pmcid: 5623555
doi: 10.1136/bmjopen-2017-016688
Kupczyk M, Barg W, Bochenek G, Brożek G, Brzostek D, Dąbrowiecki P, et al. Late Breaking Abstract - Overprescription of short-acting beta2-agonists in asthma management? Pharmacy reports from 91,673 patients in Poland. Eur Respir J. 2019;54(suppl 63):OA2107.
Molina J, Plaza V, Nuevo J, Gutiérrez M, Sicras-Mainar A, Valero A. Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study. Open Respir Arch. 2023;5(2): 100232.
pubmed: 37496866
pmcid: 10369590
doi: 10.1016/j.opresp.2023.100232
Lugogo N, Gilbert I, Tkacz J, Gandhi H, Goshi N, Lanz MJ. Real-world patterns and implications of short-acting β2-agonist use in patients with asthma in the United States. Ann Allergy Asthma Immunol. 2021;126(6):681-9.e1.
pubmed: 33515710
doi: 10.1016/j.anai.2021.01.024
Di Marco F, D’Amato M, Lombardo FP, Micheletto C, Heiman F, Pegoraro V, et al. The burden of short-acting β2-agonist use in asthma: is there an Italian case? An update from SABINA program. Adv Ther. 2021;38(7):3816–30.
pubmed: 34043208
pmcid: 8280008
doi: 10.1007/s12325-021-01772-0
Amin S, Soliman M, McIvor A, Cave A, Cabrera C. Usage patterns of short-acting β2-agonists and inhaled corticosteroids in asthma: a targeted literature review. J Allergy Clin Immunol Pract. 2020;8(8):2556-64.e8.
pubmed: 32244024
doi: 10.1016/j.jaip.2020.03.013
Quint JK, Arnetorp S, Kocks JWH, Kupczyk M, Nuevo J, Plaza V, et al. Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America. J Allergy Clin Immunol Pract. 2022;10(9):2297-309.e10.
pubmed: 35364341
doi: 10.1016/j.jaip.2022.02.047
Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–7.
pubmed: 23176877
doi: 10.1016/j.anai.2012.08.014
Azzi E, Kritikos V, Peters M, Price D, Cvetkovski B, Alphonse PS, et al. Perceptions, attitudes, and behaviors of short-acting beta2 agonist users: an Australian cross-sectional community pharmacybased study. J Asthma. 2022;59(1):178–88.
pubmed: 33086885
doi: 10.1080/02770903.2020.1841223
Jakovljevic M, Souliotis K. Pharmaceutical expenditure changes in Serbia and Greece during the global economic recession. South Eastern European Journal of Public Health. 2023. https://doi.org/10.56801/seejph.vi.74 .
doi: 10.56801/seejph.vi.74